Immunoglobulin heavy chain/light chain pair measurement is associated with survival in diffuse large B-cell lymphoma
- 18 February 2013
- journal article
- research article
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 54 (9), 1898-1907
- https://doi.org/10.3109/10428194.2013.767456
Abstract
Elevated serum free light chains (FLCs) have been associated with an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL). The aim of this study was to determine the clinical relevance of a quantitative assessment of intact circulating immunoglobulin (Ig), using serum Ig heavy chain/light chain pair (HLC) measurements in patients with DLBCL. FLC and HLC were measured in 409 serum samples of patients with DLBCL included in the LNH03-B clinical trial program of the Groupe d’Etudes des Lymphomes de l’Adulte (GELA). Patients with an abnormal IgMκ/IgMλ ratio or an abnormal FLC ratio more frequently displayed adverse clinical characteristics. Patients with abnormal IgMκ/IgMλ ratios had inferior progression-free survival (PFS) and overall survival (OS) as compared to patients with a normal ratio in the overall cohort (5-year PFS 44.9% vs. 69.3%, p = 0.0003 and 5-year OS 50.8% vs. 78.1%, p = 0.0003) and in the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) cohort (5-year OS 43.5% vs. 70.3%, p = 0.003). In multivariate analysis, including elevated FLC/HLC and International Prognostic Index (IPI), an abnormal IgMκ/IgMλ ratio (hazard ratio [HR] = 1.54, 95% confidence interval [CI] 1.03–2.3, p = 0.03) remained predictive of shorter progression-free survival. Gene expression profile experiments and immunohistochemistry indicate that this measurement is at least partially related to tumor cell secretion. Both elevated serum FLCs and an abnormal IgMκ/IgMλ ratio are associated with unfavorable outcomes in patients with DLBCL treated by R-CHOP.This publication has 32 references indexed in Scilit:
- Interleukin-6 plasma levels are modulated by a polymorphism in theNF-κB1gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphomaLeukemia & Lymphoma, 2011
- Monoclonal and polyclonal serum free light chains and clinical outcome in chronic lymphocytic leukemiaBlood, 2011
- Serum neuron-specific enolase is correlated with clinical outcome of patients with non-germinal center B cell-like subtype of diffuse large B-cell lymphoma treated with rituximab-based immunochemotherapyMedical Oncology, 2011
- Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimensEuropean Journal of Haematology, 2011
- Vitamin D Insufficiency and Prognosis in Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2010
- Detection of elevated levels of tumour‐associated microRNAs in serum of patients with diffuse large B‐cell lymphomaBritish Journal of Haematology, 2008
- Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary OriginJournal of Clinical Oncology, 2005
- Presentation Serum Selenium Predicts for Overall Survival, Dose Delivery, and First Treatment Response in Aggressive Non-Hodgkin’s LymphomaJournal of Clinical Oncology, 2003
- Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphomaCancer, 2003
- Serum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphomaLeukemia, 2001